CMG Pharmaceutical Co., Ltd.

KOSDAQ 058820.KQ

CMG Pharmaceutical Co., Ltd. Return on Assets (ROA) for the year ending December 31, 2023: 2.67%

CMG Pharmaceutical Co., Ltd. Return on Assets (ROA) is 2.67% for the year ending December 31, 2023, a 1,263.45% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

CMG Pharmaceutical Co., Ltd. Return on Assets (ROA) for the year ending December 31, 2022 was -0.23%, a -100.48% change year over year.
CMG Pharmaceutical Co., Ltd. Return on Assets (ROA) for the year ending December 31, 2021 was 47.58%, a 1,224.05% change year over year.
CMG Pharmaceutical Co., Ltd. Return on Assets (ROA) for the year ending December 31, 2020 was 3.59%, a 126.41% change year over year.
CMG Pharmaceutical Co., Ltd. Return on Assets (ROA) for the year ending December 31, 2019 was 1.59%, a 823.64% change year over year.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

KOSDAQ: 058820.KQ

CMG Pharmaceutical Co., Ltd.

CEO	Joohyung Lee
IPO Date	Nov. 19, 2001
Location	South Korea
Headquarters	Cheongdam-dong 18-20, #B01
Employees	272
Sector	Health Care
Industries Pharmaceuticals Cosmetics

Description

CMG Pharmaceutical Co., Ltd., a pharmaceutical company, develops and sells oral thin film (OTF) pharmaceuticals in South Korea. It offers Tadalafil OTF products for erectile dysfunction; Entecavir OTF products to treat hepatitis type B; Aripiprazole OTF products for schizophrenia; and Montelukast OTF products to treat asthma and allergic rhinitis. CMG Pharmaceutical Co. Ltd. has a strategic collaboration agreement with Handok Inc. for cancer treatment. The company was formerly known as Skynewpharm Co Ltd and changed its name to CMG Pharmaceutical CO., Ltd. in April 2013. CMG Pharmaceutical Co., Ltd. was founded in 2001 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years